Enhanced tumor suppression by adenoviral PTEN gene therapy combined with cisplatin chemotherapy in small-cell lung cancer

Cancer Gene Therapy

Volumn 20, Issue 4, 2013, Pages 251-259

  Li, D ^a   Zhang, Y ^a   Xie, Y ^a,b   Xiang, J ^b   Zhu, Y ^a   Yang, J ^a  

^a SOOCHOW UNIVERSITY   (China)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

chemogene therapy; cisplatin (DDP); enhanced antitumor efficacy; phosphatase and tensin homolog deleted on chromosome 10 (PTEN); small cell lung cancer (SCLC)

Indexed keywords

ADENOVIRUS VECTOR; CASPASE 3; CD34 ANTIGEN; CISPLATIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; PROTEIN P53; SURVIVIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL DENSITY; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; FEMALE; LUNG SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR XENOGRAFT; UPREGULATION;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE PROTEINS; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION; GENETIC THERAPY; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROVESSELS; NEOVASCULARIZATION, PATHOLOGIC; PTEN PHOSPHOHYDROLASE; SMALL CELL LUNG CARCINOMA; TUMOR BURDEN; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; MUS MUSCULUS;

EID: 84876949773     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2013.14     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59: 225-249.
2. Wistuba II, Gazdar AF. Lung cancer preneoplasia. Annu Rev Pathol 2006;1: 331-348.
3. Jackman DM, Johnson BE. Small-cell lung cancer. Lancet 2005;366: 1385-1396. (Pubitemid 41443406)
4. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006;24: 4539-4544. (Pubitemid 46630948)
5. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275: 1943-1947. (Pubitemid 27148818)
6. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997;15: 356-362. (Pubitemid 27147102)
7. Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 2012;13: 283-296.
8. Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. Cell 2008;133: 403-414. (Pubitemid 351622014)
9. Li DM, Sun H. PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc Natl Acad Sci USA 1998;95: 15406-15411. (Pubitemid 29018711)
10. Saito Y, Swanson X, Mhashilkar AM, Oida Y, Schrock R, Branch CD et al. Adenovirus-mediated transfer of the PTEN gene inhibits human colorectal cancer growth in vitro and in vivo. Gene Ther 2003;10: 1961-1969. (Pubitemid 37337072)
11. Jin H, Xu CX, Kim HW, Chung YS, Shin JY, Chang SH et al. Urocanic acid-modified chitosan-mediated PTEN delivery via aerosol suppressed lung tumorigenesis in K-ras(LA1) mice. Cancer Gene Ther 2008;15: 275-283. (Pubitemid 351508133)
12. Tamura M, Gu J, Takino T, Yamada KM. Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: differential involvement of focal adhesion kinase and p130Cas. Cancer Res 1999;59: 442-449. (Pubitemid 29048881)
13. Chetram MA, Odero-Marah V, Hinton CV. Loss of PTEN permits CXCR4-mediated tumorigenesis through ERK1/2 in prostate cancer cells. Mol Cancer Res 2011;9: 90-102.
14. Hwang PH, Yi HK, Kim DS, Nam SY, Kim JS, Lee DY. Suppression of tumorigenicity and metastasis in B16F10 cells by PTEN/MMAC1/TEP1 gene. Cancer Lett 2001;172: 83-91. (Pubitemid 32823476)
15. Tanaka M, Grossman HB. In vivo gene therapy of human bladder cancer with PTEN suppresses tumor growth, downregulates phosphorylated Akt, and increases sensitivity to doxorubicin. Gene Ther 2003;10: 1636-1642. (Pubitemid 37069491)
16. Tomioka A, Tanaka M, De Velasco MA, Anai S, Takada S, Kushibiki T et al. Delivery of PTEN via a novel gene microcapsule sensitizes prostate cancer cells to irradiation. Mol Cancer Ther 2008;7: 1864-1870.
17. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6: 117-127. (Pubitemid 39485684)
18. Makhov PB, Golovine K, Kutikov A, Teper E, Canter DJ, Simhan J et al. Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells. Mol Cancer Ther 2012;11: 1510-1517.
19. Kwon YW, Kim IJ, Wu D, Lu J, Stock Jr. WA, Liu Y et al. Pten regulates aurora-a and cooperates with fbxw7 in modulating radiation-induced tumor development. Mol Cancer Res 2012;10: 834-844.
20. Song MS, Carracedo A, Salmena L, Song SJ, Egia A, Malumbres M et al. Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner. Cell 2011;144: 187-199.
21. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007;7: 573-584. (Pubitemid 47106628)
22. Xie Y, Sheng W, Miao J, Xiang J, Yang J. Enhanced antitumor activity by combining an adenovirus harboring ING4 with cisplatin for hepatocarcinoma cells. Cancer Gene Ther 2011;18: 176-188.
23. Mayo LD, Dixon JE, Durden DL, Tonks NK, Donner DB. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem 2002;277: 5484-5489. (Pubitemid 34968598)
24. Wu H, Cao Y, Weng D, Xing H, Song X, Zhou J et al. Effect of tumor suppressor gene PTEN on the resistance to cisplatin in human ovarian cancer cell lines and related mechanisms. Cancer Lett 2008;271: 260-271.
25. Yokomizo A, Tindall DJ, Drabkin H, Gemmill R, Franklin W, Yang P et al. PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers. Oncogene 1998;17: 475-479. (Pubitemid 28395912)
26. Blanco R, Iwakawa R, Tang M, Kohno T, Angulo B, Pio R et al. A gene-alteration profile of human lung cancer cell lines. Hum Mutat 2009;30: 1199-1206.
27. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998;95: 2509-2514. (Pubitemid 28145972)
28. Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 1995;36: 169-180.
29. Xie Y, Lv H, Sheng W, Miao J, Xiang J, Yang J. Synergistic tumor suppression by adenovirus-mediated inhibitor of growth 4 and interleukin-24 gene cotransfer in hepatocarcinoma cells. Cancer Biother Radiopharm 2011;26: 681-695.
30. Stewart DJ. Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Crit Rev Oncol Hematol 2010;75: 173-234.
31. Kohmo S, Kijima T, Otani Y, Mori M, Minami T, Takahashi R et al. Cell surface tetraspanin CD9 mediates chemoresistance in small cell lung cancer. Cancer Res 2010;70: 8025-8035.
32. Lawson MH, Cummings NM, Rassl DM, Russell R, Brenton JD, Rintoul RC et al. Two novel determinants of etoposide resistance in small cell lung cancer. Cancer Res 2011;71: 4877-4887.
33. Wu C, Wangpaichitr M, Feun L, Kuo MT, Robles C, Lampidis T et al. Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. Mol Cancer 2005;4: 25.
34. Krystal GW, Sulanke G, Litz J. Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy. Mol Cancer Ther 2002;1: 913-922.
35. Kruse JP, Gu W. Modes of p53 regulation. Cell 2009;137: 609-622.
36. Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA 2001;98: 11598-11603. (Pubitemid 32928774)
37. Freeman DJ, Li AG, Wei G, Li HH, Kertesz N, Lesche R et al. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and-independent mechanisms. Cancer Cell 2003;3: 117-130. (Pubitemid 37443385)
38. Li AG, Piluso LG, Cai X, Wei G, Sellers WR, Liu X. Mechanistic insights into maintenance of high p53 acetylation by PTEN. Mol Cell 2006;23: 575-587. (Pubitemid 44205492)
39. Massague J. G1 cell-cycle control and cancer. Nature 2004;432: 298-306. (Pubitemid 39551657)
40. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004;116: 205-219. (Pubitemid 38167313)
41. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008;8: 61-70.
42. Belyanskaya LL, Hopkins-Donaldson S, Kurtz S, Simoes-Wust AP, Yousefi S, Simon HU et al. Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregulation. Int J Cancer 2005;117: 755-763. (Pubitemid 41598826)
43. Papapetropoulos A, Fulton D, Mahboubi K, Kalb RG, O'Connor DS, Li F et al. Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem 2000;275: 9102-9105. (Pubitemid 30185122)
44. Guha M, Plescia J, Leav I, Li J, Languino LR, Altieri DC. Endogenous tumor suppression mediated by PTEN involves survivin gene silencing. Cancer Res 2009;69: 4954-4958.
45. Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 2002;21: 2613-2622. (Pubitemid 34478319)
46. Li YM, Zhou BP, Deng J, Pan Y, Hay N, Hung MC. A hypoxia-independent hypoxiainducible factor-1 activation pathway induced by phosphatidylinositol-3 kinase/Akt in HER2 overexpressing cells. Cancer Res 2005;65: 3257-3263. (Pubitemid 40524609)
47. Maity A, Pore N, Lee J, Solomon D, O'Rourke DM. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 30-kinase and distinct from that induced by hypoxia. Cancer Res 2000;60: 5879-5886.
48. Huang J, Kontos CD. PTEN modulates vascular endothelial growth factormediated signaling and angiogenic effects. J Biol Chem 2002;277: 10760-10766. (Pubitemid 34952828)
49. Wen S, Stolarov J, Myers MP, Su JD, Wigler MH, Tonks NK et al. PTEN controls tumor-induced angiogenesis. Proc Natl Acad Sci USA 2001;98: 4622-4627. (Pubitemid 32295026)
50. Tan GH, Tian L, Wei YQ, Zhao X, Li J, Wu Y et al. Combination of low-dose cisplatin and recombinant xenogeneic endoglin as a vaccine induces synergistic antitumor activities. Int J Cancer 2004;112: 701-706. (Pubitemid 39425953)